Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)

Pharmacotherapy of acromegaly has been improved in recent years as new long-acting somatostatin analogs have became available; they have been suggested as an alternative treatment to pituitary surgery and radiotherapy. To avoid the inconvenience of multiple daily injections during long-term therapy,...

Full description

Saved in:
Bibliographic Details
Published in:The journal of clinical endocrinology and metabolism 2000-11, Vol.85 (11), p.4099-4103
Main Authors: BALDELLI, Roberto, COLAO, Annamaria, LOMBARDI, Gaetano, TAMBURRANO, Guido, RAZZORE, Paola, JAFFRAIN-REA, Marie-Lise, MARZULLO, Paolo, CICCARELLI, Enrica, FERRETTI, Elisabetta, FERONE, Diego, GAIA, Daniela, CAMANNI, Franco
Format: Article
Language:English
Subjects:
Acromegaly - blood
Acromegaly - drug therapy
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers - blood
Delayed-Action Preparations
Female
Follow-Up Studies
Hormones. Endocrine system
Human Growth Hormone - blood
Humans
Injections, Intramuscular
Insulin-Like Growth Factor I - metabolism
Male
Medical sciences
Middle Aged
Peptides, Cyclic - administration & dosage
Peptides, Cyclic - therapeutic use
Pharmacology. Drug treatments
Somatostatin - administration & dosage
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmacotherapy of acromegaly has been improved in recent years as new long-acting somatostatin analogs have became available; they have been suggested as an alternative treatment to pituitary surgery and radiotherapy. To avoid the inconvenience of multiple daily injections during long-term therapy, a slow release formulation of lanreotide (LAN), to be administered im at a dose of 30 mg every 7-14 days, has been introduced in the therapeutic management. The suppressive effects of a short-term LAN treatment on GH and insulin-like growth factor I (IGF-I) hypersecretion were shown to be similar to those obtained with sc octreotide. However, scant data have been reported concerning a long-term treatment with this drug. In the present study the efficacy and tolerability of a 24-month LAN treatment were evaluated in 118 active acromegalic patients; 71 had been previously operated on and treated with s.c. octreotide (operated patients), 24 previously operated on had been irradiated and treated with s.c. octreotide (irradiated patients), and the remaining 23 were newly diagnosed (de novo patients). The efficacy was considered on the basis of controlled GH (fasting,
ISSN:0021-972X
1945-7197
DOI:10.1210/jc.85.11.4099